BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18240153)

  • 21. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
    Ma JH; Dong C; Qiao HW; Barret O; Tamagnan GD; Mao W; Xu EH; Zhang C; Lu J; Chan P; Liu SY
    Mov Disord; 2024 May; 39(5):847-854. PubMed ID: 38477228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis.
    Lee CS; Schulzer M; de la Fuente-Fernández R; Mak E; Kuramoto L; Sossi V; Ruth TJ; Calne DB; Stoessl AJ
    Arch Neurol; 2004 Dec; 61(12):1920-5. PubMed ID: 15596613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans.
    Boileau I; Houle S; Rusjan PM; Furukawa Y; Wilkins D; Tong J; Selby P; Wilson AA; Kish SJ
    Synapse; 2010 Jun; 64(6):417-20. PubMed ID: 20169578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
    Adams JR; van Netten H; Schulzer M; Mak E; Mckenzie J; Strongosky A; Sossi V; Ruth TJ; Lee CS; Farrer M; Gasser T; Uitti RJ; Calne DB; Wszolek ZK; Stoessl AJ
    Brain; 2005 Dec; 128(Pt 12):2777-85. PubMed ID: 16081470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Visualizing vesicular dopamine dynamics in Parkinson's disease.
    de la Fuente-Fernández R; Sossi V; McCormick S; Schulzer M; Ruth TJ; Stoessl AJ
    Synapse; 2009 Aug; 63(8):713-6. PubMed ID: 19391152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome.
    Albin RL; Koeppe RA; Wernette K; Zhuang W; Nichols T; Kilbourn MR; Frey KA
    Neurology; 2009 Apr; 72(16):1390-6. PubMed ID: 19380698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pattern of striatal dopaminergic denervation explains sensorimotor synchronization accuracy in Parkinson's disease.
    Miller NS; Kwak Y; Bohnen NI; Müller ML; Dayalu P; Seidler RD
    Behav Brain Res; 2013 Nov; 257():100-10. PubMed ID: 24076152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.
    Blesa J; Juri C; Collantes M; Peñuelas I; Prieto E; Iglesias E; Martí-Climent J; Arbizu J; Zubieta JL; Rodríguez-Oroz MC; García-García D; Richter JA; Cavada C; Obeso JA
    Neurobiol Dis; 2010 Jun; 38(3):456-63. PubMed ID: 20304066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
    Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ
    Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.
    Ouchi Y; Yoshikawa E; Okada H; Futatsubashi M; Sekine Y; Iyo M; Sakamoto M
    Ann Neurol; 1999 May; 45(5):601-10. PubMed ID: 10319882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic manganism: A long-term follow-up study with a new dopamine terminal biomarker of 18F-FP-(+)-DTBZ (18F-AV-133) brain PET scan.
    Huang CY; Liu CH; Tsao E; Hsieh CJ; Weng YH; Hsiao IT; Yen TC; Lin KJ; Huang CC
    J Neurol Sci; 2015; 353(1-2):102-6. PubMed ID: 25936253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
    De La Fuente-Fernández R; Furtado S; Guttman M; Furukawa Y; Lee CS; Calne DB; Ruth TJ; Stoessl AJ
    Synapse; 2003 Jul; 49(1):20-8. PubMed ID: 12710012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias.
    Troiano AR; de la Fuente-Fernandez R; Sossi V; Schulzer M; Mak E; Ruth TJ; Stoessl AJ
    Neurology; 2009 Apr; 72(14):1211-6. PubMed ID: 19020294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interpreting DTBZ binding data in rodent: Inherent variability and compensation.
    Mejias M; Yu J; Mackey S; Dinelle K; Sossi V; Doudet DJ
    Synapse; 2016 Apr; 70(4):147-52. PubMed ID: 26749375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of 11C-(+)-alpha -dihydrotetrabenazine for the assessment of dopaminergic innervation in animal models of Parkinson's disease].
    Collantes M; Peñuelas I; Alvarez-Erviti L; Blesa J; Martí-Climent JM; Quincoces G; Delgado M; Ecay M; Martínez A; Arbizu J; Rodríguez-Oroz MC; Obeso J; Richter JA
    Rev Esp Med Nucl; 2008; 27(2):103-11. PubMed ID: 18367048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects.
    Weng YH; Yen TC; Chen MC; Kao PF; Tzen KY; Chen RS; Wey SP; Ting G; Lu CS
    J Nucl Med; 2004 Mar; 45(3):393-401. PubMed ID: 15001678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
    Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
    Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET imaging a MPTP-induced mouse model of Parkinson's disease using the fluoropropyl-dihydrotetrabenazine analog [18F]-DTBZ (AV-133).
    Toomey JS; Bhatia S; Moon LT; Orchard EA; Tainter KH; Lokitz SJ; Terry T; Mathis JM; Penman AD
    PLoS One; 2012; 7(6):e39041. PubMed ID: 22723923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.